Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The lead product Proclarix® is a blood based prostate cancer test panel and risk score introduced to the market early 2020.
Proteomedix has been acquired by Blue Water Biotech.
Products, services, technology
Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient`s risk of having clinically significant prostate cancer.
- http://www.proteomedix.com
- +41 44 733 40 90
- contact@proteomedix.com
- Christian Brühlmann
